These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 30165887)
1. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. Giannotti F; Labopin M; Shouval R; Sanz J; Arcese W; Angelucci E; Sierra J; Santasusana JR; Santarone S; Benedetto B; Rambaldi A; Saccardi R; Blaise D; Carella MA; Rocha V; Baron F; Mohty M; Ruggeri A; Nagler A J Hematol Oncol; 2018 Aug; 11(1):110. PubMed ID: 30165887 [TBL] [Abstract][Full Text] [Related]
2. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346 [TBL] [Abstract][Full Text] [Related]
3. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A; Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639 [TBL] [Abstract][Full Text] [Related]
4. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bazarbachi A; Labopin M; Blaise D; Forcade E; Socié G; Berceanu A; Angelucci E; Bulabois CE; Kröger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M Bone Marrow Transplant; 2021 Mar; 56(3):622-634. PubMed ID: 33020591 [TBL] [Abstract][Full Text] [Related]
5. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325 [TBL] [Abstract][Full Text] [Related]
6. Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. El-Cheikh J; Labopin M; Al-Chami F; Bazarbachi A; Angelucci E; Santarone S; Bonifazi F; Carella AM; Castagna L; Bruno B; Iori AP; La Nasa G; Savani B; Nagler A; Mohty M Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):296-304. PubMed ID: 32081702 [TBL] [Abstract][Full Text] [Related]
7. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565 [TBL] [Abstract][Full Text] [Related]
8. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Swoboda R; Labopin M; Giebel S; Angelucci E; Arat M; Aljurf M; Sica S; Pavlu J; Socié G; Bernasconi P; Rigacci L; Tischer J; Risitano A; Rovira M; Saccardi R; Pioltelli P; Van Gorkom G; Vitek A; Savani BN; Spyridonidis A; Peric Z; Nagler A; Mohty M Bone Marrow Transplant; 2022 Mar; 57(3):399-406. PubMed ID: 35031709 [TBL] [Abstract][Full Text] [Related]
9. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Sestili S; Labopin M; Ruggeri A; Velardi A; Ciceri F; Maertens J; Kanz L; Aversa F; Lewalle P; Bunjes D; Mohty M; Nagler A Cancer; 2018 May; 124(10):2142-2150. PubMed ID: 29469924 [TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Ruggeri A; Sanz G; Bittencourt H; Sanz J; Rambaldi A; Volt F; Yakoub-Agha I; Ribera JM; Mannone L; Sierra J; Mohty M; Solano C; Nabhan S; Arcese W; Gluckman E; Labopin M; Rocha V; Leukemia; 2014 Apr; 28(4):779-86. PubMed ID: 24005245 [TBL] [Abstract][Full Text] [Related]
11. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. Sora F; Grazia CD; Chiusolo P; Raiola AM; Bregante S; Mordini N; Olivieri A; Iori AP; Patriarca F; Grisariu S; Terruzzi E; Rambaldi A; Sica S; Bruno B; Angelucci E; Bacigalupo A Biol Blood Marrow Transplant; 2020 Apr; 26(4):698-703. PubMed ID: 31875522 [TBL] [Abstract][Full Text] [Related]
14. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871 [TBL] [Abstract][Full Text] [Related]
15. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457 [TBL] [Abstract][Full Text] [Related]
18. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Kwon M; Bautista G; Balsalobre P; Sánchez-Ortega I; Montesinos P; Bermúdez A; de Laiglesia A; Herrera P; Martin C; Humala K; Zabalza A; Torres M; Bento L; Corral LL; Heras I; Serrano D; Buño I; Anguita J; Regidor C; Duarte R; Cabrera R; Gayoso J; Diez-Martin JL Bone Marrow Transplant; 2017 Aug; 52(8):1138-1143. PubMed ID: 28346415 [TBL] [Abstract][Full Text] [Related]
19. When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). Esquirol A; Querol S; Garcia-Cadenas I; Novelli S; Garrido A; Saavedra S; Moreno C; Granell M; Caballero A; Brunet S; Briones J; Martino R; Sierra J Ann Hematol; 2020 Jan; 99(1):157-165. PubMed ID: 31844931 [TBL] [Abstract][Full Text] [Related]
20. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]